Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans
Standard
Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans. / Harrer, Caroline E; Mayer, Leonie; Fathi, Anahita; Lassen, Susan; Ly, My L; Zinser, Madeleine E; Wolf, Timo; Becker, Stephan; Sutter, Gerd; Dahlke, Christine; Addo, Marylyn M; MVA-MERS-S Study Group.
in: J INFECT DIS, Jahrgang 230, Nr. 2, 16.08.2024, S. e327-e332.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans
AU - Harrer, Caroline E
AU - Mayer, Leonie
AU - Fathi, Anahita
AU - Lassen, Susan
AU - Ly, My L
AU - Zinser, Madeleine E
AU - Wolf, Timo
AU - Becker, Stephan
AU - Sutter, Gerd
AU - Dahlke, Christine
AU - Addo, Marylyn M
AU - MVA-MERS-S Study Group
N1 - © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
PY - 2024/8/16
Y1 - 2024/8/16
N2 - Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The modified vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing the MERS-CoV-spike glycoprotein (MERS-S), is one of 3 candidate vaccines in clinical development and elicits robust humoral and cellular immunity. Here, we identified for the first time a MERS-S-specific CD8+ T-cell epitope in an HLA-A*03:01/HLA-B*35:01-positive vaccinee using a screening assay, intracellular cytokine staining, and in silico epitope prediction. As evidence from MERS-CoV infection suggests a protective role of long-lasting CD8+ T-cell responses, the identification of epitopes will facilitate longitudinal analyses of vaccine-induced T-cell immunity.
AB - Licensed vaccines against the Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging pathogen of concern, are lacking. The modified vaccinia virus Ankara vector-based vaccine MVA-MERS-S, expressing the MERS-CoV-spike glycoprotein (MERS-S), is one of 3 candidate vaccines in clinical development and elicits robust humoral and cellular immunity. Here, we identified for the first time a MERS-S-specific CD8+ T-cell epitope in an HLA-A*03:01/HLA-B*35:01-positive vaccinee using a screening assay, intracellular cytokine staining, and in silico epitope prediction. As evidence from MERS-CoV infection suggests a protective role of long-lasting CD8+ T-cell responses, the identification of epitopes will facilitate longitudinal analyses of vaccine-induced T-cell immunity.
U2 - 10.1093/infdis/jiad612
DO - 10.1093/infdis/jiad612
M3 - SCORING: Journal article
C2 - 38195212
VL - 230
SP - e327-e332
JO - J INFECT DIS
JF - J INFECT DIS
SN - 0022-1899
IS - 2
ER -